Vancouver, British Columbia – May 9, 2018 — LED Medical Diagnostics Inc. (“LED” or the “Company”) (TSX-V: LMD) participated in the annual Bloom Burton & Co. Healthcare Investor Conference May 2 and 3, 2018 as a presenting Company. The conference took place at the Sheraton Centre Toronto Hotel with Bloom Burton & Co. showcasing approximately sixty of the premier Canadian healthcare companies, including LED, to its network of investors from across Canada, the U.S. and Europe. Investors had the opportunity to meet with LED management and receive a corporate update.LED also announced that it has granted a total of 660,000 stock options exercisable at CDN$0.42 per share to directors, officers, consultants and employees in accordance with its stock option plan. The options are for a term of up to 5 years and generally vest over a three-year period.About LED Medical Diagnostics Inc.
LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Apteryx, Inc., LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. LED’s proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Apteryx’s XrayVision, XVWeb and XrayVision DCV imaging software solutions.
Backed by an experienced leadership team and dedicated to a higher level of service and support, LED is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSX-V under the symbol LMD, the OTCQB under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.